{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:44:17Z","timestamp":1793245457085,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40264-023-01320-5","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T08:02:26Z","timestamp":1687334546000},"page":"819-833","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0487-7996","authenticated-orcid":false,"given":"Emanuel","family":"Raschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Fusaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Burgazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Potena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"1320_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2: e192535.","journal-title":"JAMA Netw Open"},{"key":"1320_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003024","volume":"10","author":"O Michielin","year":"2022","unstructured":"Michielin O, Lalani A-K, Robert C, Sharma P, Peters S. Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. J Immunother Cancer. 2022;10: e003024.","journal-title":"J Immunother Cancer"},{"key":"1320_CR3","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","volume":"6","author":"B Shankar","year":"2020","unstructured":"Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, et\u00a0al. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol. 2020;6:1952\u20136.","journal-title":"JAMA Oncol"},{"key":"1320_CR4","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C, Ye F, et\u00a0al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721\u20138.","journal-title":"JAMA Oncol"},{"key":"1320_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40264-018-0774-8","volume":"42","author":"I Baraibar","year":"2019","unstructured":"Baraibar I, Melero I, Ponz-Sarvise M, Castanon E. Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer. Drug Saf. 2019;42:281\u201394.","journal-title":"Drug Saf"},{"key":"1320_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et\u00a0al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563\u201380.","journal-title":"Nat Rev Clin Oncol"},{"key":"1320_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102452","volume":"110","author":"M Kfoury","year":"2022","unstructured":"Kfoury M, Najean M, Lappara A, Voisin A-L, Champiat S, Michot J-M, et\u00a0al. Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. Cancer Treat Rev. 2022;110: 102452.","journal-title":"Cancer Treat Rev"},{"key":"1320_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40265-022-01707-1","volume":"82","author":"S Kanji","year":"2022","unstructured":"Kanji S, Morin S, Agtarap K, Purkayastha D, Thabet P, Bosse D, et\u00a0al. Adverse events associated with immune checkpoint inhibitors: overview of systematic reviews. Drugs. 2022;82:793\u2013809.","journal-title":"Drugs"},{"key":"1320_CR9","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28:2377\u201385.","journal-title":"Ann Oncol"},{"key":"1320_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2021.04.045","volume":"153","author":"H Dearden","year":"2021","unstructured":"Dearden H, Au L, Wang DY, Zimmer L, Eroglu Z, Smith JL, et\u00a0al. Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. Eur J Cancer. 2021;153:168\u201378.","journal-title":"Eur J Cancer"},{"key":"1320_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","volume":"149","author":"E Ghisoni","year":"2021","unstructured":"Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, et\u00a0al. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy. Eur J Cancer. 2021;149:153\u201364.","journal-title":"Eur J Cancer"},{"key":"1320_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","volume":"15","author":"E Raschi","year":"2020","unstructured":"Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance. Target Oncol. 2020;15:449\u201366.","journal-title":"Target Oncol"},{"key":"1320_CR13","first-page":"1316","volume":"20","author":"AB Khalid","year":"2022","unstructured":"Khalid AB, Calderon G, Jalal SI, Durm GA. Physician awareness of immune-related adverse events of immune checkpoint inhibitors. J Natl Compr Cancer Netw JNCCN. 2022;20:1316\u201320.","journal-title":"J Natl Compr Cancer Netw JNCCN."},{"key":"1320_CR14","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et\u00a0al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"},{"key":"1320_CR15","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et\u00a0al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217\u201338.","journal-title":"Ann Oncol"},{"key":"1320_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, et\u00a0al. Management of immunotherapy-related toxicities, version 1. 2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw JNCCN. 2022;20:387\u2013405.","journal-title":"J Natl Compr Cancer Netw JNCCN."},{"key":"1320_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et\u00a0al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9: e002435.","journal-title":"J Immunother Cancer"},{"key":"1320_CR18","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et\u00a0al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361.","journal-title":"Eur Heart J"},{"key":"1320_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et\u00a0al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43:280\u201399.","journal-title":"Eur Heart J"},{"key":"1320_CR20","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19:e447\u201358.","journal-title":"Lancet Oncol"},{"key":"1320_CR21","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1093\/eurheartj\/ehac456","volume":"43","author":"F Thuny","year":"2022","unstructured":"Thuny F, Naidoo J, Neilan TG. Cardiovascular complications of immune checkpoint inhibitors for cancer. Eur Heart J. 2022;43:4458\u201368.","journal-title":"Eur Heart J"},{"key":"1320_CR22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/annonc\/mdx718","volume":"29","author":"F Gelsomino","year":"2018","unstructured":"Gelsomino F, Fiorentino M, Zompatori M, Poerio A, Melotti B, Sperandi F, et\u00a0al. Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques? Ann Oncol. 2018;29:284\u20136.","journal-title":"Ann Oncol"},{"key":"1320_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jacc.2021.11.048","volume":"79","author":"JT Vuong","year":"2022","unstructured":"Vuong JT, Stein-Merlob AF, Nayeri A, Sallam T, Neilan TG, Yang EH. Immune checkpoint therapies and atherosclerosis: mechanisms and clinical implications: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79:577\u201393.","journal-title":"J Am Coll Cardiol"},{"key":"1320_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejca.2022.07.018","volume":"177","author":"J Nowatzke","year":"2022","unstructured":"Nowatzke J, Guedeney P, Palaskas N, Lehmann L, Ederhy S, Zhu H, et\u00a0al. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: report from an international registry. Eur J Cancer. 2022;177:197\u2013205.","journal-title":"Eur J Cancer"},{"key":"1320_CR25","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et\u00a0al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"1320_CR26","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et\u00a0al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136:2085\u20137.","journal-title":"Circulation"},{"key":"1320_CR27","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem J-E, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391:933.","journal-title":"Lancet"},{"key":"1320_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000261","volume":"8","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, et\u00a0al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020;8: e000261.","journal-title":"J Immunother Cancer"},{"key":"1320_CR29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jacc.2019.11.059","volume":"75","author":"JM Bonsu","year":"2020","unstructured":"Bonsu JM, Guha A, Charles L, Yildiz VO, Wei L, Baker B, et\u00a0al. Reporting of cardiovascular events in clinical trials supporting FDA approval of contemporary cancer therapies. J Am Coll Cardiol. 2020;75:620\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1320_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem J-E, Wiviott SD, Ederhy S, Cohen A, et\u00a0al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140:80\u201391.","journal-title":"Circulation"},{"key":"1320_CR31","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et\u00a0al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749\u201355.","journal-title":"N Engl J Med"},{"key":"1320_CR32","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"J-E Salem","year":"2018","unstructured":"Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et\u00a0al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579\u201389.","journal-title":"Lancet Oncol"},{"key":"1320_CR33","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1200\/JCO.22.00369","volume":"40","author":"AR Naqash","year":"2022","unstructured":"Naqash AR, Moey MYY, Cherie Tan X-W, Laharwal M, Hill V, Moka N, et\u00a0al. Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the National Cancer Institute-Cancer Therapy evaluation program. J Clin Oncol. 2022;40:3439\u201352.","journal-title":"J Clin Oncol"},{"key":"1320_CR34","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","volume":"42","author":"C Dolladille","year":"2021","unstructured":"Dolladille C, Akroun J, Morice P-M, Dompmartin A, Ezine E, Sassier M, et\u00a0al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. 2021;42:4964\u201377.","journal-title":"Eur Heart J"},{"key":"1320_CR35","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/ejhf.2289","volume":"23","author":"N Rubio-Infante","year":"2021","unstructured":"Rubio-Infante N, Ram\u00edrez-Flores YA, Castillo EC, Lozano O, Garc\u00eda-Rivas G, Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021;23:1739\u201347.","journal-title":"Eur J Heart Fail"},{"key":"1320_CR36","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et\u00a0al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142:2299\u2013311.","journal-title":"Circulation"},{"key":"1320_CR37","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","volume":"42","author":"M D\u2019Souza","year":"2021","unstructured":"D\u2019Souza M, Nielsen D, Svane IM, Iversen K, Rasmussen PV, Madelaire C, et\u00a0al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J. 2021;42:1621\u201331.","journal-title":"Eur Heart J"},{"key":"1320_CR38","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.21.01808","volume":"40","author":"D Laenens","year":"2022","unstructured":"Laenens D, Yu Y, Santens B, Jacobs J, Beuselinck B, Bechter O, et\u00a0al. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol. 2022;40:3430\u20138.","journal-title":"J Clin Oncol"},{"key":"1320_CR39","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.3390\/cancers14184494","volume":"14","author":"R Jim\u00e9nez-Alejandre","year":"2022","unstructured":"Jim\u00e9nez-Alejandre R, Ruiz-Fern\u00e1ndez I, Mart\u00edn P. Pathophysiology of immune checkpoint inhibitor-induced myocarditis. Cancers. 2022;14:4494.","journal-title":"Cancers"},{"key":"1320_CR40","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.3390\/ijms21093054","volume":"21","author":"AG Solimando","year":"2020","unstructured":"Solimando AG, Crudele L, Leone P, Argentiero A, Guarascio M, Silvestris N, et\u00a0al. Immune checkpoint inhibitor-related myositis: from biology to bedside. Int J Mol Sci. 2020;21:3054.","journal-title":"Int J Mol Sci"},{"key":"1320_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2018.08.007","volume":"95","author":"P Kumar","year":"2018","unstructured":"Kumar P, Bhattacharya P, Prabhakar BS. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. J Autoimmun. 2018;95:77\u201399.","journal-title":"J Autoimmun"},{"key":"1320_CR42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00262-016-1930-6","volume":"66","author":"I Kwiecien","year":"2017","unstructured":"Kwiecien I, Stelmaszczyk-Emmel A, Polubiec-Kownacka M, Dziedzic D, Domagala-Kulawik J. Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humans. Cancer Immunol Immunother. 2017;66:161\u201370.","journal-title":"Cancer Immunol Immunother"},{"key":"1320_CR43","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/bph.15984","volume":"180","author":"TG Gergely","year":"2023","unstructured":"Gergely TG, Kucsera D, T\u00f3th VE, Kov\u00e1cs T, Sayour NV, Drobni ZD, et\u00a0al. Molecular characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals IL-17A as a driver of cardiac dysfunction after anti-PD-1 treatment. Br J Pharmacol. 2023;180:740\u201361.","journal-title":"Br J Pharmacol"},{"key":"1320_CR44","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, et\u00a0al. T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis. Nature. 2022;611:818\u201326.","journal-title":"Nature"},{"key":"1320_CR45","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","volume":"26","author":"R Pathak","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 2021;26:1052\u201361.","journal-title":"Oncologist"},{"key":"1320_CR46","doi-asserted-by":"crossref","unstructured":"Rossi S, Cani I, Raschi E, Comito F, Rinaldi R, Ardizzoni A, et\u00a0al. Neurological manifestations as a harbinger of myocarditis in patients treated with immune checkpoint inhibitors. J Clin Oncol. 2022;JCO2201602.","DOI":"10.1200\/JCO.22.01602"},{"key":"1320_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.884776","volume":"13","author":"Y Nakagomi","year":"2022","unstructured":"Nakagomi Y, Tajiri K, Shimada S, Li S, Inoue K, Murakata Y, et\u00a0al. Immune checkpoint inhibitor-related myositis overlapping with myocarditis: an institutional case series and a systematic review of literature. Front Pharmacol. 2022;13: 884776.","journal-title":"Front Pharmacol"},{"key":"1320_CR48","first-page":"689","volume":"4","author":"A Vasbinder","year":"2022","unstructured":"Vasbinder A. Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor-induced myocarditis. J Am Coll Cardiol CardioOnc. 2022;4:689\u2013700.","journal-title":"J Am Coll Cardiol CardioOnc."},{"key":"1320_CR49","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et\u00a0al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35:893\u2013911.","journal-title":"J Clin Oncol"},{"key":"1320_CR50","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et\u00a0al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72:3158\u201376.","journal-title":"J Am Coll Cardiol"},{"key":"1320_CR51","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/ejhf.2265","volume":"23","author":"NL Palaskas","year":"2021","unstructured":"Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, et\u00a0al. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail. 2021;23:1725\u201335.","journal-title":"Eur J Heart Fail"},{"key":"1320_CR52","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Y Adler","year":"2015","unstructured":"Adler Y, Charron P, Imazio M, Badano L, Bar\u00f3n-Esquivias G, Bogaert J, et\u00a0al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36:2921\u201364.","journal-title":"Eur Heart J"},{"key":"1320_CR53","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jcmg.2017.11.036","volume":"11","author":"S Ederhy","year":"2018","unstructured":"Ederhy S, Cautela J, Ancedy Y, Escudier M, Thuny F, Cohen A. Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors. JACC Cardiovasc Imaging. 2018;11:1187\u201390.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1320_CR54","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11886-016-0730-0","volume":"18","author":"F Viganego","year":"2016","unstructured":"Viganego F, Singh R, Fradley MG. Arrhythmias and other electrophysiology issues in cancer patients receiving chemotherapy or radiation. Curr Cardiol Rep. 2016;18:52.","journal-title":"Curr Cardiol Rep"},{"key":"1320_CR55","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1080\/10428194.2018.1533129","volume":"60","author":"R Lentz","year":"2019","unstructured":"Lentz R, Feinglass J, Ma S, Akhter N. Risk factors for the development of atrial fibrillation on ibrutinib treatment. Leuk Lymphoma. 2019;60:1447\u201353.","journal-title":"Leuk Lymphoma"},{"key":"1320_CR56","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.bbmt.2013.05.019","volume":"19","author":"A Singla","year":"2013","unstructured":"Singla A, Hogan WJ, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, et\u00a0al. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2013;19:1233\u20137.","journal-title":"Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl."},{"key":"1320_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002007","volume":"9","author":"DA Zlotoff","year":"2021","unstructured":"Zlotoff DA, Hassan MZO, Zafar A, Alvi RM, Awadalla M, Mahmood SS, et\u00a0al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021;9: e002007.","journal-title":"J Immunother Cancer"},{"key":"1320_CR58","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","volume":"34","author":"H Mir","year":"2018","unstructured":"Mir H, Alhussein M, Alrashidi S, Alzayer H, Alshatti A, Valettas N, et\u00a0al. Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area. Can J Cardiol. 2018;34:1059\u201368.","journal-title":"Can J Cardiol"},{"key":"1320_CR59","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","volume":"5","author":"Y Zamami","year":"2019","unstructured":"Zamami Y, Niimura T, Okada N, Koyama T, Fukushima K, Izawa-Ishizawa Y, et\u00a0al. Factors associated with immune checkpoint inhibitor-related myocarditis. JAMA Oncol. 2019;5:1635\u20137.","journal-title":"JAMA Oncol"},{"key":"1320_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178607","volume":"12","author":"S Bando","year":"2017","unstructured":"Bando S, Soeki T, Matsuura T, Tobiume T, Ise T, Kusunose K, et\u00a0al. Plasma brain natriuretic peptide levels are elevated in patients with cancer. PLoS ONE. 2017;12: e0178607.","journal-title":"PLoS ONE"},{"key":"1320_CR61","first-page":"6","volume":"5","author":"S Upadhrasta","year":"2019","unstructured":"Upadhrasta S, Elias H, Patel K, Zheng L. Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med. 2019;5:6\u201314.","journal-title":"Chronic Dis Transl Med."},{"key":"1320_CR62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","volume":"3","author":"L Zhang","year":"2021","unstructured":"Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: CardioOncology primer. JACC CardioOncology. 2021;3:35\u201347.","journal-title":"JACC CardioOncology."},{"key":"1320_CR63","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","volume":"6","author":"FC Santini","year":"2018","unstructured":"Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, et\u00a0al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res. 2018;6:1093\u20139.","journal-title":"Cancer Immunol Res"},{"key":"1320_CR64","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","volume":"24","author":"A Pavan","year":"2019","unstructured":"Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, et\u00a0al. Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Oncologist. 2019;24:1128\u201336.","journal-title":"Oncologist"},{"key":"1320_CR65","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jdermsci.2017.07.007","volume":"88","author":"Y Fujisawa","year":"2017","unstructured":"Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Fujimura T, Yamamoto Y, et\u00a0al. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab. J Dermatol Sci. 2017;88:225\u201331.","journal-title":"J Dermatol Sci"},{"key":"1320_CR66","first-page":"160","volume":"39","author":"G Vinco","year":"2018","unstructured":"Vinco G. P868. Neutrophil-to-lymphocyte ratio at the onset of acute myocarditis reflects the extent of myocardial necrosis. Eur Heart J Suppl. 2018;39:160.","journal-title":"Eur Heart J Suppl."},{"key":"1320_CR67","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018306","volume":"9","author":"ZD Drobni","year":"2020","unstructured":"Drobni ZD, Zafar A, Zubiri L, Zlotoff DA, Alvi RM, Lee C, et\u00a0al. Decreased absolute lymphocyte count and increased neutrophil\/lymphocyte ratio with immune checkpoint inhibitor-associated myocarditis. J Am Heart Assoc. 2020;9: e018306.","journal-title":"J Am Heart Assoc"},{"key":"1320_CR68","first-page":"548","volume":"30","author":"L Casciola-Rosen","year":"2012","unstructured":"Casciola-Rosen L, Hall J, Mammen A, Christopher-Stine L, Rosen A. Isolated elevation of aldolase in the serum of myositis patients: a potential biomarker of damaged early regenerating muscle cells. Clin Exp Rheumatol. 2012;30:548\u201353.","journal-title":"Clin Exp Rheumatol"},{"key":"1320_CR69","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J, et\u00a0al. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology. 2021;96:754\u201366.","journal-title":"Neurology"},{"key":"1320_CR70","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00262-021-03053-9","volume":"71","author":"M Seki","year":"2022","unstructured":"Seki M, Kitano S, Suzuki S. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies. Cancer Immunol Immunother. 2022;71:769\u201375.","journal-title":"Cancer Immunol Immunother"},{"key":"1320_CR71","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1002\/ejhf.1985","volume":"22","author":"JL Zamorano","year":"2020","unstructured":"Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, et\u00a0al. The cancer patient and cardiology. Eur J Heart Fail. 2020;22:2290\u2013309.","journal-title":"Eur J Heart Fail"},{"key":"1320_CR72","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10549-021-06192-w","volume":"188","author":"NML Battisti","year":"2021","unstructured":"Battisti NML, Andres MS, Lee KA, Ramalingam S, Nash T, Mappouridou S, et\u00a0al. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Res Treat. 2021;188:149\u201363.","journal-title":"Breast Cancer Res Treat"},{"key":"1320_CR73","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","volume":"133","author":"RJ Koene","year":"2016","unstructured":"Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133:1104\u201314.","journal-title":"Circulation"},{"key":"1320_CR74","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ejca.2022.08.010","volume":"175","author":"A R\u00fcnger","year":"2022","unstructured":"R\u00fcnger A, Schadendorf D, Hauschild A, Gebhardt C. Immune checkpoint blockade for organ-transplant recipients with cancer: a review. Eur J Cancer. 2022;175:326\u201335.","journal-title":"Eur J Cancer"},{"key":"1320_CR75","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejca.2021.01.038","volume":"148","author":"LS Nguyen","year":"2021","unstructured":"Nguyen LS, Ortuno S, Lebrun-Vignes B, Johnson DB, Moslehi JJ, Hertig A, et\u00a0al. Transplant rejections associated with immune checkpoint inhibitors: a pharmacovigilance study and systematic literature review. Eur J Cancer. 2021;148:36\u201347.","journal-title":"Eur J Cancer"},{"key":"1320_CR76","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.3390\/cancers14215403","volume":"14","author":"C Zito","year":"2022","unstructured":"Zito C, Manganaro R, Ciappina G, Spagnolo CC, Racanelli V, Santarpia M, et\u00a0al. Cardiotoxicity induced by immune checkpoint inhibitors: what a cardio-oncology team should know and do. Cancers. 2022;14:5403.","journal-title":"Cancers"},{"key":"1320_CR77","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ejca.2020.09.032","volume":"141","author":"M Aldea","year":"2020","unstructured":"Aldea M, Orillard E, Mansi L, Marabelle A, Scotte F, Lambotte O, et\u00a0al. How to manage patients with corticosteroids in oncology in the era of immunotherapy? Eur J Cancer. 2020;141:239\u201351.","journal-title":"Eur J Cancer"},{"key":"1320_CR78","doi-asserted-by":"publisher","first-page":"10292","DOI":"10.3390\/ijms231810292","volume":"23","author":"A De Giglio","year":"2022","unstructured":"De Giglio A, Aprile M, Di Federico A, Sperandi F, Melotti B, Gelsomino F, et\u00a0al. Impact of baseline versus intercurrent steroids administration on upfront chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC). Int J Mol Sci. 2022;23:10292.","journal-title":"Int J Mol Sci"},{"key":"1320_CR79","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.3390\/cancers12102827","volume":"12","author":"A De Giglio","year":"2020","unstructured":"De Giglio A, Mezquita L, Auclin E, Blanc-Durand F, Riudavets M, Caramella C, et\u00a0al. Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (NSCLC) patients under immune-checkpoint inhibitors (ICI). Cancers. 2020;12:2827.","journal-title":"Cancers"},{"key":"1320_CR80","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","volume":"141","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, et\u00a0al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation. 2020;141:2031\u20134.","journal-title":"Circulation"},{"key":"1320_CR81","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"J-E Salem","year":"2019","unstructured":"Salem J-E, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et\u00a0al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380:2377\u20139.","journal-title":"N Engl J Med"},{"key":"1320_CR82","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004699","volume":"10","author":"LS Nguyen","year":"2022","unstructured":"Nguyen LS, Bretagne M, Arrondeau J, Zahr N, Ederhy S, Abbar B, et\u00a0al. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. J Immunother Cancer. 2022;10: e004699.","journal-title":"J Immunother Cancer"},{"key":"1320_CR83","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1056\/NEJMc1903064","volume":"380","author":"K Esfahani","year":"2019","unstructured":"Esfahani K, Buhlaiga N, Th\u00e9bault P, Lapointe R, Johnson NA, Miller WH. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N Engl J Med. 2019;380:2375\u20136.","journal-title":"N Engl J Med"},{"key":"1320_CR84","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/bjc.2017.253","volume":"117","author":"RY Tay","year":"2017","unstructured":"Tay RY, Blackley E, McLean C, Moore M, Bergin P, Gill S, et\u00a0al. Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer. 2017;117:921\u20134.","journal-title":"Br J Cancer"},{"key":"1320_CR85","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/CJI.0000000000000239","volume":"41","author":"V Jain","year":"2018","unstructured":"Jain V, Mohebtash M, Rodrigo ME, Ruiz G, Atkins MB, Barac A. Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin. J Immunother. 2018;41:332\u20135.","journal-title":"J Immunother"},{"key":"1320_CR86","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40959-021-00095-x","volume":"7","author":"RS Zhang","year":"2021","unstructured":"Zhang RS, Padegimas A, Murphy KM, Evans PT, Peters CJ, Domenico CM, et\u00a0al. Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with infliximab: a case series. Cardio-Oncol Lond Engl. 2021;7:13.","journal-title":"Cardio-Oncol Lond Engl."},{"key":"1320_CR87","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","volume":"31","author":"J Doms","year":"2020","unstructured":"Doms J, Prior JO, Peters S, Obeid M. Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. Ann Oncol. 2020;31:1273\u20135.","journal-title":"Ann Oncol"},{"key":"1320_CR88","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00392-020-01648-3","volume":"110","author":"S Peleg Hasson","year":"2021","unstructured":"Peleg Hasson S, Salwen B, Sivan A, Shamai S, Geva R, Merimsky O, et\u00a0al. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis. Clin Res Cardiol. 2021;110:50\u201360.","journal-title":"Clin Res Cardiol"},{"key":"1320_CR89","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1038\/s41591-022-02094-6","volume":"28","author":"S Groha","year":"2022","unstructured":"Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, et\u00a0al. Germline variants associated with toxicity to immune checkpoint blockade. Nat Med. 2022;28:2584\u201391.","journal-title":"Nat Med"},{"key":"1320_CR90","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2217\/imt-2022-0172","volume":"15","author":"E Raschi","year":"2023","unstructured":"Raschi E, Comito F, Massari F, Gelsomino F. Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY. Immunotherapy. 2023;15:85\u201391.","journal-title":"Immunotherapy"},{"key":"1320_CR91","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1200\/JCO.21.01806","volume":"40","author":"BI Rini","year":"2022","unstructured":"Rini BI, Moslehi JJ, Bonaca M, Schmidinger M, Albiges L, Choueiri TK, et\u00a0al. Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: data from the phase III JAVELIN renal 101 trial. J Clin Oncol. 2022;40:1929\u201338.","journal-title":"J Clin Oncol"},{"key":"1320_CR92","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41571-021-00597-8","volume":"19","author":"Y Jing","year":"2022","unstructured":"Jing Y, Yang J, Johnson DB, Moslehi JJ, Han L. Harnessing big data to characterize immune-related adverse events. Nat Rev Clin Oncol. 2022;19:269\u201380.","journal-title":"Nat Rev Clin Oncol"},{"key":"1320_CR93","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002896","volume":"9","author":"KL Reynolds","year":"2021","unstructured":"Reynolds KL, Arora S, Elayavilli RK, Louv WC, Schaller TH, Khandelwal A, et\u00a0al. Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. J Immunother Cancer. 2021;9: e002896.","journal-title":"J Immunother Cancer"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01320-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-023-01320-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01320-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:05:32Z","timestamp":1692662732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-023-01320-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":93,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1320"],"URL":"https:\/\/doi.org\/10.1007\/s40264-023-01320-5","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"10 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Alma Mater Studiorum - Universit\u00e0 di Bologna within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no potential conflict of interest relevant to the content of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ER conceptualized the manuscript. SR, ADG, and LP contributed in the design of the manuscript. MF contributed to visualization. ER wrote the original draft, with contribution of SR and ADG. All the authors contributed to the editing of the draft. All the authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}